Zepbound (tirzepatide) is FDA-approved for weight loss in adults with obesity or with overweight and a weight-related health condition
Blood sugar management, metabolic health, kidney health, heart risk, and medication alternatives are medical decisions
It also stimulates focal adhesion kinase (FAK)-paxillin complexes, which help cells migrate and attach during tissue reconstruction
Reactive oxygen species as mediators of cellular senescence
In people with T2DM, elevated risk of peripheral arterial disease, ischaemic stroke, stable angina, HF and non-fatal MI was observed
Tirzepatide's binding kinetics at GLP-1R result in lower beta-arrestin recruitment relative to cAMP generation, a biased agonism profile, which may partly explain the sustained glucose-lowering effect observed across 40 weeks in SURPASS-2 [19]